NCT05607810 - Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Diabetic Macular EdemaDiabetic Retinopathy

Interventions

GENETIC

ADVM-022

Long term follow-up of subjects who previously received ADVM-022

Trial Locations (7)

Adverum Clinical Site, Philadelphia

Adverum Clinical Site, Bellaire

Adverum Clinical Site, The Woodlands

Adverum Clinical Site, Austin

Adverum Clinical Site, Reno

Adverum Clinical Site, Beverly Hills

Adverum Clinical Site, Arecibo